Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

153.88 -1.93 (-1.24%)
Streaming Delayed Price Updated: 9:30 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
News headline image
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Acquire MiroBio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Second Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a... 
Via MarketBeat
News headline image
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period 
Via SBWire
News headline image
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Joining the Global Access to Oncology Medicines Coalition
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.